Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.
Completed Phase 3 RECOVER OLE 1-year trial: brilaroxazine sustained PANSS total score -18.1 over 1 year.
FDA meeting planned Q4 2025 for path to approval; potential NDA submission targeted Q2 2026.
Completed $10.0M public equity offering in Q2 2025.
Plans to assess registrational Phase 3 RECOVER-2 pending FDA feedback; IND for psoriasis formulation expected Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.